Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedDec 31, 2025
DataAggregated Company Financials
Companies21
  • 7D-1.7%
  • 3M-9.0%
  • 1Y-41.3%
  • YTD-42.6%

Over the last 7 days, the Healthcare industry has risen 5.9%, driven by gains from Novo Nordisk of 8.0%. In contrast, the industry has lost 41% in the last 12 months. Earnings are forecast to grow by 4.5% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 31 Dec 2025DKK 1.9tDKK 453.7bDKK 136.8b17.2x14.2x4.3x
Fri, 28 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.5x13.8x4.2x
Sun, 26 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.7x14.3x4.5x
Tue, 23 Sep 2025DKK 2.2tDKK 447.2bDKK 141.6b18.9x15.5x4.9x
Thu, 21 Aug 2025DKK 2.0tDKK 444.6bDKK 139.8b29.5x14.4x4.5x
Sat, 19 Jul 2025DKK 2.3tDKK 423.3bDKK 124.5b29.9x18.4x5.4x
Mon, 16 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.4x22.3x6.5x
Wed, 14 May 2025DKK 2.4tDKK 423.4bDKK 124.9b23x19.1x5.6x
Fri, 11 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.2x18.6x5.5x
Sun, 09 Mar 2025DKK 3.2tDKK 409.5bDKK 121.3b27x26.1x7.7x
Tue, 04 Feb 2025DKK 3.3tDKK 387.8bDKK 111.4b28.2x29.2x8.4x
Thu, 02 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.9x29.6x8.5x
Sat, 30 Nov 2024DKK 3.9tDKK 387.3bDKK 111.3b31.2x35.2x10.1x
Mon, 28 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34x37.9x10.9x
Wed, 25 Sep 2024DKK 4.3tDKK 371.9bDKK 107.1b37x40.1x11.5x
Fri, 23 Aug 2024DKK 4.7tDKK 371.9bDKK 107.1b36.3x43.9x12.6x
Sun, 21 Jul 2024DKK 4.6tDKK 355.3bDKK 106.2b35.6x43.3x12.9x
Tue, 18 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.7x46.2x13.8x
Thu, 16 May 2024DKK 4.7tDKK 355.4bDKK 106.6b35.3x43.8x13.1x
Sat, 13 Apr 2024DKK 4.5tDKK 341.3bDKK 99.7b33.5x45.1x13.2x
Mon, 11 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.6x46.7x13.6x
Wed, 07 Feb 2024DKK 4.2tDKK 338.6bDKK 98.5b34.8x42.3x12.3x
Fri, 05 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.1x41.9x11.8x
Sun, 03 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.8x40.3x11.3x
Tue, 31 Oct 2023DKK 3.5tDKK 305.6bDKK 82.3b26.5x42.5x11.4x
Thu, 28 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b32.9x41.5x11.2x
Sat, 26 Aug 2023DKK 3.4tDKK 305.2bDKK 82.1b35.4x41.2x11.1x
Mon, 24 Jul 2023DKK 3.0tDKK 287.0bDKK 75.4b40.6x40.1x10.6x
Wed, 21 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.7x10.4x
Fri, 19 May 2023DKK 3.2tDKK 285.6bDKK 74.6b41.4x42.4x11.1x
Sun, 16 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b43x46x11.6x
Tue, 14 Mar 2023DKK 2.7tDKK 292.6bDKK 69.2b37.1x39.7x9.4x
Thu, 09 Feb 2023DKK 2.8tDKK 287.5bDKK 68.7b38x40.1x9.6x
Sat, 07 Jan 2023DKK 2.8tDKK 276.1bDKK 66.3b38.3x41.5x10x
Price to Earnings Ratio

41.5x


Total Market Cap: DKK 2.8tTotal Earnings: DKK 66.3bTotal Revenue: DKK 276.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 34.1x20242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 14.3x which is lower than its 3-year average PE of 34.1x.
  • The 3-year average PS ratio of 9.5x is higher than the industry's current PS ratio of 4.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.14%
Healthcare-1.70%
Healthtech3.74%
Medical Equipment0.50%
Life Sciences0.38%
Pharma-1.76%
Biotech-3.88%
Healthcare Services-7.16%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 176x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 94% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 20% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 546.400.7%
+DKK 811.3m		-30.5%PE33.9x
DEMANT DemantDKK 215.200.6%
+DKK 255.6m		-18.5%PE17.2x
ALK B ALK-AbellóDKK 228.600.4%
+DKK 221.2m		43.7%PE45.9x
HLUN B H. LundbeckDKK 43.160.4%
+DKK 158.6m		4.5%PE11.2x
BAVA Bavarian NordicDKK 190.850.7%
+DKK 109.6m		0.8%PE6.1x

Latest News

HLUN B
DKK 43.16
H. Lundbeck
7D
0.4%
1Y
4.5%

HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements

Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.
ZEAL
DKK 466.40
Zealand Pharma
7D
-3.4%
1Y
-34.8%

ZEAL: Next Generation Metabolic Partnership Will Drive Future Upside Potential

Analysts have nudged their price target for Zealand Pharma slightly higher to approximately $774 per share from about $773, citing modestly lower discount rate assumptions. These more than offset slightly weaker long term revenue growth and profit margin expectations.
NOVO B
DKK 325.25
Novo Nordisk
7D
-1.9%
1Y
-47.9%

NOVO B: Future Returns Will Rely On Durable Obesity And Diabetes Cash Flows

Analysts have nudged their fair value estimate for Novo Nordisk slightly lower by about $0.25 per share to roughly $393.04, reflecting modestly softer long term revenue growth assumptions even as profit margin and valuation expectations remain broadly intact. Analyst Commentary Analyst sentiment around Novo Nordisk remains broadly constructive, with the slight fair value adjustment seen more as a recalibration of growth expectations than a shift in the underlying thesis.
ALK B
DKK 228.60
ALK-Abelló
7D
0.4%
1Y
43.7%
DEMANT
DKK 215.20
Demant
7D
0.6%
1Y
-18.5%
BAVA
DKK 190.85
Bavarian Nordic
7D
0.7%
1Y
0.8%
AMBU B
DKK 88.00
Ambu
7D
0.3%
1Y
-15.4%

AMBU B: Dividend And Share Buybacks Will Drive Future Upside Potential

Analysts have trimmed their price target for Ambu slightly, lowering fair value by about 1 dollar per share as modestly slower expected revenue growth and profit margins are only partly offset by a slightly higher future P/E multiple and lower discount rate. What's in the News Ambu has launched a new share repurchase program starting December 10, 2025, allowing buybacks of up to 10% of its share capital under a mandate valid until December 13, 2027 (company announcement) The company announced an annual dividend of DKK 0.41 per share, payable on December 8, 2025, with an ex date of December 4 and record date of December 5, 2025 (company announcement) For fiscal 2025/26, Ambu issued guidance for 10% to 13% organic growth and an EBIT margin of 12% to 14%, or 14% to 16% excluding roughly 2 percentage points of tariff impacts (company guidance) Ambu reaffirmed its 2024/25 financial guidance, maintaining expectations for 12% to 14% organic revenue growth (company guidance) Valuation Changes Fair Value Estimate edged down slightly from DKK 115.59 to DKK 114.79 per share, reflecting a modestly lower fundamental valuation.
COLO B
DKK 546.40
Coloplast
7D
0.7%
1Y
-30.5%
EMBLA
DKK 32.50
Embla Medical hf
7D
-0.9%
1Y
-8.7%

EMBLA: Ukraine Expansion And Margin Outlook Will Support Steady Future Performance

Analysts have raised their price target for Embla Medical hf. from approximately 28.00 dollars to 34.00 dollars, reflecting expectations for slightly faster revenue growth, improving profit margins, and a higher justified future earnings multiple, despite a modestly higher discount rate.
SMSMED
DKK 4.41
Scandinavian Medical Solutions
7D
-7.2%
1Y
-26.0%
GMAB
DKK 2,027.00
Genmab
7D
-4.5%
1Y
35.8%

GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels

Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.
BIOPOR
DKK 1.02
BioPorto
7D
-1.9%
1Y
-34.2%
PEG
DKK 0.093
Pharma Equity Group
7D
-0.2%
1Y
-50.8%
NNIT
DKK 49.80
NNIT
7D
3.9%
1Y
-46.2%
CHEMM
DKK 687.50
ChemoMetec
7D
0.6%
1Y
41.4%
MONSO
DKK 0.15
Monsenso
7D
-6.3%
1Y
-59.2%